Viewing Study NCT01335256


Ignite Creation Date: 2025-12-24 @ 11:16 PM
Ignite Modification Date: 2026-05-19 @ 7:00 AM
Study NCT ID: NCT01335256
Status: COMPLETED
Last Update Posted: 2013-05-03
First Post: 2011-01-10
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Clinical Study to Evaluate Safety and Maximum Tolerated Dose of BAY1000394 Given in a 4 Week on / 2 Week Off Schedule in Subjects With Advanced Malignancies
Sponsor: Bayer
Organization:

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Neoplasms View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Phase I, dose escalation, kinase inhibitor, cyclin-dependent kinase inhibitor, target … View